Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Neuroleptic or [[:Category:Antihypertensives|Antihypertensive (historical)]]

Use the filters below to narrow your results.

generic:
Asenapine (1) · Chlorpromazine (1) · Droperidol (1) · Fluphenazine (1) · Guanfacine (1) · Iloperidone (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Paliperidone (1) · Perphenazine (1) · Pimozide (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)
brand:
Fanapt (1) · Geodon (1) · Inapsine (1) · Intuniv (extended-release), Tenex (immediate-release) (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Phenothiazine D2 antagonist (4) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000019-QINU`"' Sedation and hypotension are the dose-limiting effects; gradual titration and bedtime or split dosing mitigate both. Abrupt discontinuation can precipitate rebound hypertension, particularly with long-standing use'"`UNIQ--ref-0000001A-QINU`"'. (1)
uses:
None (15) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1)
starting dose:
None (15) · Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response (1)
preparations:
None (15) · Extended-release tablets 1, 2, 3, 4 mg (Intuniv); immediate-release tablets 1, 2 mg (Tenex) (1)
fda max:
None (15) · 7 mg/day in children and adolescents; weight-based ceiling (~0.12 mg/kg/day) applies in smaller patients (1)
routes:
None (15) · Oral (1)
onset:
None (15) · Gradual; full clinical effect over 2-4 weeks of titration (1)
duration:
None (15) · ~24 hours (ER formulation supports once-daily dosing) (1)
halflife:
None (15) · ~17-18 hours (Intuniv ER); ~17 hours (immediate-release)'"`UNIQ--ref-00000020-QINU`"' (1)
bioavailability:
None (15) · ~58% (extended-release); ~80% (immediate-release)'"`UNIQ--ref-00000021-QINU`"' (1)
pregnancy:
None (15) · Limited human data. Animal studies show fetal effects at maternally toxic doses; use only if benefits justify the potential risk.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (15) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful contrast to the psychostimulant alternatives for ADHD'"`UNIQ--ref-00000022-QINU`"' (1)

Showing below up to 16 results in range #1 to #16.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"